Antibody Drug Conjugates_AMR

Antibody Drug Conjugates - A Groundbreaking Solution to Cancer
In pursuit of more targeted therapies and clinically effective drugs, pharmaceutical companies
are increasing their research and development activities in biologics. Although a majority of this
work is focused on monoclonal antibodies (mAbs) and recombinant proteins, progress is being
made in specialized drugs. Antibody drug conjugates (ADCs) are a new class of drugs that is
gaining attention from both large and small pharmaceutical companies as they offer promise in
cancer therapeutics. They consist of an mAb - an antibody that is specific to the target associated
antigen, a cytotoxic drug - designed to kill target cancer cells, and a linker - that attaches the
cytotoxic agent to the antibody. Thus, antibody drug conjugates combine the targeting ability of
monoclonal antibody and the target specific cell killing ability of cytotoxic drugs.
The market for antibody drug conjugates is witnessing a fast growth, which is supported by the
advancement in medical technology, the rise in the occurrence of cancer cases worldwide,
growing ageing population, and the growing obese population. Furthermore, the increased
research activities on antibody therapies, advanced drug discoveries and oncology diseases as
well as the growing collaboration between research institutes are propelling the growth of the
industry. Nonetheless, the high cost of the procedures and the lack of fund pose a threat to the
growth of the ADC market. According to a report published by Allied Market Research, the
antibody drug conjugates market is expected to reach $3,198 million by 2023, registering a CAGR
of 12.9% from 2017 to 2023.
Companies within the space are coming up with superior technologies to develop more effective
and efficient antibody drug conjugates. For instance, ADC Therapeutics, a developer of
proprietary PBD-based antibody drug conjugates, recently announced that it would deliver its
presentations regarding strong preclinical data for its two new investigational programs ADCT-
601 targeting AXL and ADCT-701 targeting DLK-1 at the American Association for Cancer Research
(AACR) Annual Meeting. Daiichi Sankyo, a global pharmaceutical company announced that its
HER2-targeting antibody drug conjugate (ADC) received SAKIGAKE Designation for the treatment
of gastric cancer by the Japan Ministry of Health, Labor and Welfare (MHLW). Synaffix, a
Netherlands-based biotech company announced the launch of a new platform of highly potent
cytotoxic ADC payloads that integrates into its existing ADC platform.
ADC Therapeutics to Present Two Novel ADCs
In April 2018, ADC Therapeutics announced its presentation regarding strong preclinical data for
its two new investigational programs ADCT-601 targeting AXL and ADCT-701 targeting DLK-1 at

the American Association for Cancer Research (AACR) Annual Meeting which takes place from
April 14-18, 2018 in Chicago, USA. Dr. Jay Feingold, Chief Medical Officer and Senior Vice
President of Clinical Development at ADCT said, “Our two new investigational programs show
compelling efficacy and safety in preclinical studies. These results provide an important step to
advance ADCT-601 and ADCT-701 into the clinic and enlarge our pipeline of PBD-based ADCs in
multiple ongoing clinical trials for the treatment of both solid and hematological cancers.”
Highlights of the data to be presented are available on the AACR conference website at
www.aacr.org
Daiichi Sankyo's HER2-Targeting Antibody Drug Conjugate Receives SAKIGAKE Designation for
Gastric Cancer
In March 2018, Daiichi Sankyo announced that DS-8201, an HER2-targeting antibody drug
conjugate (ADC) received SAKIGAKE Designation for the treatment of HER2-positive advanced
gastric or gastroesophageal junction cancer by the Japan Ministry of Health, Labor, and Welfare
(MHLW). The company said that it intends to work closely with the Japan MHLW under the terms
of the SAKIGAKE program to speed up the development of DS-8201 since Japan has one of the
highest cases of gastric cancer worldwide. The SAKIGAKE Designation system fosters R&D in
Japan, propelling early practical application for novel pharmaceutical products, medical devices,
and regenerative medicines. As a designated medicine under the system, DS-8201 has prioritized
consultation, a dedicated review system to support the development and review process, and a
reduced review time.
Synaffix Launches toxSYN, a New Platform of ADC Payloads
Synaffix BV, a biotechnology company announced thgrowinge launch of a new platform of
cytotoxic ADC payloads that integrates into its current ADC platform. With the launch, the
company becomes a provider of technologies needed to quickly translate antibodies into
proprietary ADC products. The new toxSYN platform comprises four highly potent payloads
offering multiple mechanisms of action and a way for commercialization when integrated with
the components of Synaffix’s GlycoConnect and HydraSpace technologies. Validated clinically
with well-known efficacy and safety profiles, the payloads were selected to address the two types
of biologies that exist across ADC targets such as rapidly-dividing cancer cells and quiescent cells.
“We expect this important expansion of our ADC technology to further advance our internal
research and facilitate collaborations with a much broader set of companies,” said Peter van de
Sande, CEO of Synaffix. “By providing these four distinct payloads through our new toxSYN
platform, we can now enable any company with an existing antibody to rapidly establish a highlycompetitive
clinical-stage ADC program for its own development pipeline.”
Read more at: https://www.alliedmarketresearch.com/antibody-drug-caonjugate-market